VRAX logo

VIRAX BIOLABS GROUP LTD

VRAXNASDAQ
🏆 #5348 by market capUS Equity
$2.32▼ $0.08 (−3.33%)
Live
🔔
Track VRAX
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 3.3%
7d▼ 9.0%
14d▼ 12.0%
30d▼ 21.2%
ytd▼ 76.0%
1y▼ 84.3%
🏦Market Cap
$2M
Small Cap
📈Revenue Growth (YoY)
+96.4%
High Growth
📊Gross Margin
62.0%
High
💵FCF Margin
—
⚖️P/S Ratio
265.9x
Expensive
Otter Score
68
Fair

Trading Snapshot

Day Range
$2.31 – $2.34
52-Week Range
$2.15 – $21.75
Volume
$3.52B
Avg Volume
$2.61B
Shares Outstanding
800,000
Next Earnings
Dec 15, 2026

Fundamentals Snapshot

Annual Revenue
$7,852
Last Q Revenue
$1,971
P/E Ratio
—
P/S Ratio
265.9x
EPS (TTM)
$-23.09
Dividend Yield
—

Why Investors Own VRAX

  • ✓High-growth profile — revenue up +24.2% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 75% gross margin and 9% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

VRAX logo

VIRAX BIOLABS GROUP LTD

VRAX
Financial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$7,852▲ +26.5% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
74.7%▲ +3.7% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$2,725▲ +26.5% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$699▲ +26.5% YoY
StockOtter · stockotter.space

About VIRAX BIOLABS GROUP LTD

Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100

Analyst Price Target

ⓘ
Average Target
$2.55
▲ +9.9% Upside
High Target$3.11
Low Target$1.97
Based on 15 analysts

Latest News & Updates

🚀
Barron’s·2h ago

VIRAX BIOLABS GROUP LTD tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift VRAX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

VIRAX BIOLABS GROUP LTD announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.